Mission Therapeutics CEO on clinical strategy for DUB drugs

Mission Therapeutics CEO Anker Lundemose outlines the company's emerging DUB drug discovery platform, speaking to Scrip senior editor Lucie Ellis about the company's progressing clinical strategy that will see its primary compound enter human trials in the first half of 2019. Lundemose, as the chief executive of a UK biotech, highlights his concerns around Brexit— particularly how changes could limit access to the best scientific talent across Europe.
Mission is the leading company in deubiquitylating enzyme (DUB) drug discovery and development. DUBs have emerged as key drug targets across a broad range of diseases from mitochondrial disease, fibrosis, neurodegeneration, inflammation and cancer.  As an example, Mission was recently awarded a grant from the Michael J Fox Foundation to investigate the role of DUBs in Parkinson’s disease. Mission has prioritized four first-in-class, small molecule DUB target programs in its pipeline based on extensive research of the almost 100 human DUBs and their market opportunities.